Evidence map›Paper›PMID 42162015›Full record

ReviewNPJ vaccines2026

Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation.

Liwei Hong, Juju Zhou, Junjuan Tan, Xiaoqian Zhu, Weihan Chen, Song Xie, Baotian Huang, Kai Chen

Abstract readReview
In one paragraph

Review in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liwei Hong *Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Juju Zhou *Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Junjuan Tan *Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Xiaoqian ZhuCancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Weihan ChenCancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Song XieCancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Baotian HuangCancer Hospital of Shantou University Medical College, Shantou, Guangdong, China. hbt830910@126.com.
Kai ChenCancer Hospital of Shantou University Medical College, Shantou, Guangdong, China. chenkai89@126.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515140141Institutional Cultivation Project of the National Natural Science Foundation of China 2025GP004National Natural Science Foundation of China 82100195
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is a ubiquitous oncogenic virus linked to malignancies and autoimmune diseases. No licensed vaccines are currently available. Recent advances in EBV biology have enabled rational antigen selection and accelerated development of multivalent vaccines using platforms such as mRNA and nanoparticles. This review outlines key mechanisms, vaccine targets, and platform innovations, and discusses major challenges and future directions for EBV vaccine development.

Identifiers

PMID42162015
PMCPMC13458768

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.